Antiosteoporotic activity of anthraquinones from Morinda officinalis on osteoblasts and osteoclasts.
Bioactivity-guided fractionation led to the successful isolation of antiosteoporotic components, i.e. physicion (1), rubiadin-1-methyl ether (2), 2-hydroxy-1-methoxy- anthraquinone (3), 1,2-dihydroxy-3-methylanthraquinone (4), 1,3,8-trihydroxy-2-methoxy- anthraquinone (5), 2-hydroxymethyl-3-hydroxyanthraquinone (6), 2-methoxyanthraquinone (7) and scopoletin (8) from an ethanolic extract of the roots of Morinda officinalis. Compounds 4-8 are isolated for the first time from M. officinalis. Among them, compounds 2 and 3 promoted osteoblast proliferation, while compounds 4, 5 increased osteoblast ALP activity. All of the isolated compounds inhibited osteoclast TRAP activity and bone resorption, and the inhibitory effects on osteoclastic bone resorption of compounds 1 and 5 were stronger than that of other compounds. Taken together, antiosteoporotic activity of M. officinalis and its anthraquinones suggest therapeutic potential against osteoporosis.
Wu
Yan-Bin
YB
Department of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, PR China. wxsq1@163.com
Zheng
Cheng-Jian
CJ
Qin
Lu-Ping
LP
Sun
Lian-Na
LN
Han
Ting
T
Jiao
Lei
L
Zhang
Qiao-Yan
QY
Wu
Jin-Zhong
JZ
D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D000880:Anthraquinones / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D001862:Bone Resorption / Q000188:drug therapy; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D015394:Molecular Structure; D032066:Morinda / Q000737:chemistry*; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects*; D010010:Osteoclasts / Q000166:cytology / Q000187:drug effects*; D051381:Rats; D017208:Rats, Wistar
D000880:Anthraquinones; D050071:Bone Density Conservation Agents; D000469:Alkaline Phosphatase